Last reviewed · How we verify
NCT05372562
Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX
trial in Macular Edema in 30 participants. Completed in 30 April 2022.
30 April 2022
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 July 2017 |
| Primary completion | 30 April 2022 |
| Estimated completion | 30 April 2022 |
| Sites | 1 location across China |
Conditions studied
- Macular Edema — all drugs for Macular Edema →
Sponsor
Peking University
Who can join
Eligibility, any sex, with Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients who were diagnosed as postoperative CME and administrated with intravitreal OZURDEX injection were reviewed. Outcome will include best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT). Recurrent CME and corresponding treatments were recorded.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Recent Achievements and Perspectives in Smart Nano-in-Micro Platforms for Ocular Disease Treatment.
Huang Y, Yan D, Ouyang W, Hu J, et al · · 2025 · cited 1× · PMID 40546796 · DOI 10.2147/ijn.s518643
Verify or expand the search:
- PubMed search for NCT05372562
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Macular Edema
Currently open trials in the same condition.
- NCT06962839 — A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema · Phase 2 · recruiting
- NCT06686641 — Incidence of Macular Edema in a Uveitis Population · active not recruiting
- NCT05976139 — Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies · NA · recruiting
- NCT05698329 — Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macula · Phase 1 · active not recruiting
- NCT06595355 — Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin · Phase 2, PHASE3 · recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05372562 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 12 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05372562.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing